Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses

Journal of Gene Medicine

Volumn 2, Issue 5, 2000, Pages 353-360

  Wildner, Oliver ^a,c   Morris, John C ^a,b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Adenovirus; Cancer gene therapy; Fail safe gene; HSV 1 tk GCV system; Peritoneal carcinomatosis; Viral oncolysis

Indexed keywords

ADENOVIRIDAE; HERPES; HUMAN ADENOVIRUS TYPE 5; HUMAN HERPESVIRUS 1; MUS MUSCULUS;

ANTIVIRUS AGENT; GANCICLOVIR; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL STRAIN HT29; COLON TUMOR; CYTOPATHOGENIC EFFECT; ENZYMOLOGY; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS 1; HUMAN; METASTASIS; METHODOLOGY; MOUSE; NUDE MOUSE; PERITONEUM TUMOR; SAFETY; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; COLONIC NEOPLASMS; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HT29 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PERITONEAL NEOPLASMS; SAFETY; THYMIDINE KINASE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034279442     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-2254(200009/10)2:5<353::AID-JGM130>3.0.CO;2-G     Document Type: Article

References (52)

1. Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391-399.
2. Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996; 20: 585-591.
3. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3: 1354-1361.
4. Puumalainen AM, Vapalahti M, Agrawal RS, et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998; 9: 1769-1774.
5. Harsh GR, Deisboeck TS, Louis DN, et al. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 2000; 92: 804-811.
6. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: parading for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
7. Norrby E. Viral vaccines: the use of currently available products and future developments. Arch Virol 1983; 76: 163-177.
8. Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211-1218.
9. Southam CM. Present status of oncolytic virus studies. Trans N Y Acad Sci 1960; 22: 657-673.
10. Asada T. Treatment of human cancer with mumps virus. Cancer 1974; 34: 1907-1928.
11. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of genetically engineered virus mutant. Science 1991; 252: 854-856.
12. Bischoff JR, Kim DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
13. Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994; 54: 5745-5751.
14. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-1333.
15. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of HSV-tk. Cancer Res 1999; 59: 410-413.
16. Widner O, Morris JC, Vahanian NN, Ford HJ, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the eficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999; 6: 57-62.
17. Wilener O, Morris JC. The role of the E1B 55 kDa gene in oncolytic adenoviral vectors expressing HSV-tk: assessment of anti-tumor efficacy and toxicity. Cancer Res 2000 60: 4167-4174.
18. Ghattas IR, Sanes JR, Majors JE. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 1991; 11: 5848-5859.
19. Morgan RA, Couture L, Elroy-Stein O, Ragheb J, Moss B, Anderson WF. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 1992; 20: 1293-1299.
20. Okada T, Ramsey WJ, Munir J, Wildner O, Blaese RM. Efficient directional cloning of recombinant adnovirus vectors using DNA-protein complex. Nucleic Acids Res 1998; 26: 1947-1950.
21. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 1994; 91: 8802-8806.
22. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207-220.
23. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
24. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
25. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977; 59: 221-226.
26. Santoso JT, Tang DC, Lane SB, et al. Adenovirus-based p53 gene therapy in ovarian cancer [see comments]. Gynecol Oncol 1995; 59: 171-178.
27. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
28. Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl) guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem 1993; 268: 6332-6337.
29. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59: 410-413.
30. Ishii-Morita H, Agbaria R, Mullen CA, et al. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 1997; 4: 244-251.
31. Chen CY, Chang YN, Ryan P, Linscott M, McGarrity GJ, Chiang YL. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect". Hum Gene Ther 1995; 6: 1467-1476.
32. Boucher PD, Ruch RJ, Shewach DS. Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum Gene Ther 1998; 9: 801-814.
33. Goodrum FD, Ornelles DA. The early region IB 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral raplication by the cell cycle. J Virol 1997; 71: 548-561.
34. Goodrum FD, Ornelles DA. p53 Status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998; 72: 9479-9490.
35. Hay JG, Shapiro N, Sauthoff H, Heitner S, Phupakdi W, Rom WN. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum Gene Ther 1999; 10: 579-590.
36. Goldsmith KT, Dion LD, Curiel DT, Garver RI, Jr. Trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus. Virology 1998; 248: 406-419.
37. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, Zur HH. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470-9478.
38. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-Dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4: 1068-1072.
39. Turnell AS, Grand RJ, Gallimore PH. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol 1999; 73: 2074-2083.
40. Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999; 73: 5333-5344.
41. Morris JC, Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000; 1: 56-62.
42. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107-121.
43. Babiss LE, Ginsberg HS, Darnell JE Jr. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol Cell Biol 1985; 5: 2552-2558.
44. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virl 1996; 70: 2296-2306.
45. Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994; 48: 455-484.
46. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998; 16: 444-448.
47. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999; 59: 3861-3865.
48. Cook SD. Antiviral agents for ocular adenovirus infections. Eye 1993; 7: 18-20.
49. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-2245.
50. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-4352.
51. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4: 581-587.
52. Morris JC, Ramsey WJ, Wildner O, Muslow HA, Aguilar-Cordova E, Blaese RM. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther 2000; 11: 487-503.